PMID- 24521887
OWN - NLM
STAT- MEDLINE
DCOM- 20140915
LR  - 20201209
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 93
IP  - 44
DP  - 2013 Nov 26
TI  - [Jinghuaweikang gelatin pearls plus proton pump inhibitor-based triple regimen in 
      the treatment of chronic atrophic gastritis with Helicobacter pylori infection: a 
      multicenter, randomized, controlled clinical study].
PG  - 3491-5
AB  - OBJECTIVE: To observe the efficacy of Jinghuaweikang gelatin pearls plus proton 
      pump inhibitor (PPI)-based triple regimen in the treatment of chronic atrophic 
      gastritis (CAG) patients with Helicobacter pylori (H.pylori) infection. METHODS: 
      For this multicenter, randomized, controlled clinical study, 90 patients of 
      endoscopically confirmed CAG with positive H.pylori ((13)C or (14)C-urea breath 
      test (UBT) or rapid urease test) were enrolled. There were 46 males and 44 
      females with an age range of (54 +/- 10) years. None of them had H.pylori 
      eradication background. They were randomly divided into 2 groups, Group LACJ (n = 
      45) received lansoprazole 30 mg+amoxicillin 1000 mg+clarithromycin 500 mg + 
      jinghuaweikang gelatin pearls 240 mg, twice daily, for 10 days (d1-10) plus 
      another 14 days (d11-24) only with jinghuaweikang gelatin pearls 240 mg, twice 
      daily. Group LACB (n = 45) had standard quadruple regimen treatment: lansoprazole 
      30 mg+amoxicillin 1000 mg+clarithromycin 500 mg+bismuth potassium citrate 220 mg, 
      twice daily for 10 days (d1-10). The status of H.pylori was detected by (13)C-UBT 
      at least 28 days after therapy. RESULTS: The eradication rates in Groups LACJ and 
      LACB were as follows: per-protocol (PP): 70.5% (31/44) and 83.3% (35/42), 
      intention-to-treat (ITT): 68.9% (31/45) and 77.8% (35/45) (both P > 0.05). The 
      symptomatic improvements of bloating in upper abdomen, belching and epigastric 
      pain after treatment in both groups. And those in Group LACJ was higher than 
      those of Group LACB, but no statistical difference existed between two groups 
      (all P > 0.05). CONCLUSIONS: The efficacy of LACJ for the treatment of CAG 
      patients with H.pylori infection is similar to LACB. And the symptomatic 
      improvement of patients is better than LACB.
FAU - Wang, Ting-ting
AU  - Wang TT
AD  - Department of Integrated Traditional & Western Medicine, Beijing University First 
      Hospital, Beijing 100034, China.
FAU - Zhang, Yue-miao
AU  - Zhang YM
FAU - Zhang, Xue-zhi
AU  - Zhang XZ
AD  - Email: zhang.xuezhi@263.net.
FAU - Cheng, Hong
AU  - Cheng H
FAU - Hu, Fu-lian
AU  - Hu FL
FAU - Han, Hai-xiao
AU  - Han HX
FAU - Chen, Xiao-wei
AU  - Chen XW
FAU - Li, Jun-xiang
AU  - Li JX
FAU - Lai, Yao-liang
AU  - Lai YL
FAU - Liu, Yong
AU  - Liu Y
LA  - chi
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (jinghua weikang)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/administration & dosage/*therapeutic use
MH  - Female
MH  - Gastritis, Atrophic/*drug therapy/microbiology
MH  - Helicobacter Infections/*drug therapy
MH  - Helicobacter pylori
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/administration & dosage/*therapeutic use
EDAT- 2014/02/14 06:00
MHDA- 2014/09/16 06:00
CRDT- 2014/02/14 06:00
PHST- 2014/02/14 06:00 [entrez]
PHST- 2014/02/14 06:00 [pubmed]
PHST- 2014/09/16 06:00 [medline]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2013 Nov 26;93(44):3491-5.